Health Boards
Galapagos a clinical stage biotech company based in Belgium today announced that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ osteoarthritis alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK €34M in additional milestones plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.
“Inhibition of JAK1 is considered a promising new therapeutic route to treat inflammatory diseases. Galapagos is leading the field with two JAK1 inhibition molecules being tested in patients,” said Onno van de Stolpe, CEO of Galapagos. “With two of our JAK1 molecules in Phase 2, we hope that this will deliver a new class of medicines to patients with inflammatory diseases.”
GSK plans to initiate a 12 week, multi-center, dose-ranging, placebo-controlled Phase 2 study investigating safety and efficacy of various doses of GSK2586184 in SLE patients. Furthermore, GSK will also initiate a 12 week multi-center, dose-ranging, placebo-controlled Phase 2 study investigating the efficacy and safety of GSK2586184 in chronic plaque psoriasis.
Source: glpg.com
GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ osteoarthritis alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK €34M in additional milestones plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.
“Inhibition of JAK1 is considered a promising new therapeutic route to treat inflammatory diseases. Galapagos is leading the field with two JAK1 inhibition molecules being tested in patients,” said Onno van de Stolpe, CEO of Galapagos. “With two of our JAK1 molecules in Phase 2, we hope that this will deliver a new class of medicines to patients with inflammatory diseases.”
GSK plans to initiate a 12 week, multi-center, dose-ranging, placebo-controlled Phase 2 study investigating safety and efficacy of various doses of GSK2586184 in SLE patients. Furthermore, GSK will also initiate a 12 week multi-center, dose-ranging, placebo-controlled Phase 2 study investigating the efficacy and safety of GSK2586184 in chronic plaque psoriasis.
Source: glpg.com
